









Markets
/
Stocks
/
nasdaq-bcab
/

Bioatla Inc

BCAB

0.645USD

-0.028-4.22%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

37.88MMarket Cap

LossP/E TTM



Bioatla Inc

0.645

-0.028-4.22%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bioatla Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bioatla Inc's Score

Industry at a Glance

Industry Ranking

126 / 407

Overall Ranking

258 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

10.000

Target Price

+1384.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bioatla Inc Highlights

StrengthsRisks

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.00M.

Overvalued

The company’s latest PE is -0.59, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 16.73M shares, decreasing 58.83% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 754.24K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.14, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.73

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.27

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Bioatla Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 8.66, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.59, which is -63.81% below the recent high of -0.21 and -414.06% above the recent low of -3.02.

Score

Industry at a Glance

Previous score

8.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 126/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Bioatla Inc is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

10.000

Target Price

+1384.78%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Bioatla Inc

BCAB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.04, which is lower than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 0.94 and the support level at 0.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.35

Change

-0.31

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.033

Neutral

RSI(14)

45.105

Neutral

STOCH(KDJ)(9,3,3)

25.045

Sell

ATR(14)

0.094

Low Volatility

CCI(14)

-101.183

Sell

Williams %R

76.617

Sell

TRIX(12,20)

-0.241

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

0.675

Sell

MA10

0.700

Sell

MA20

0.748

Sell

MA50

0.685

Sell

MA100

0.530

Buy

MA200

0.467

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 28.49%, representing a quarter-over-quarter decrease of 34.13%. The largest institutional shareholder is The Vanguard, holding a total of 1.78M shares, representing 3.04% of shares outstanding, with 3.85% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Acorn Capital Advisors, LLC

4.84M

OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.

3.55M

Short (Jay M)

2.52M

-0.25%

The Vanguard Group, Inc.

Star Investors

1.78M

-1.92%

Acadian Asset Management LLC

1.49M

-11.69%

Tang Capital Management, LLC

1.37M

Short (Carolyn Anderson)

1.35M

Smith Scott Andrew

852.35K

+2.84%

Renaissance Technologies LLC

Star Investors

754.24K

+1.26%

Aguja Capital GmbH

750.00K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.77, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.03. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.